|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2005-5-24
|
|
pubmed:abstractText |
Alemtuzumab, a humanized monoclonal antibody directed against human CD52, has a strong lympholytic effect. This study evaluates the safety of unmanipulated peripheral blood stem-cell transplantation from two or three loci-mismatched related donors using alemtuzumab in vivo.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0041-1337
|
|
pubmed:author |
pubmed-author:Asano-MoriYukiY,
pubmed-author:ChibaShigeruS,
pubmed-author:HangaishiAkiraA,
pubmed-author:HiraiHisamaruH,
pubmed-author:IzutsuKojiK,
pubmed-author:KandaYoshinobuY,
pubmed-author:KandabashiKojiK,
pubmed-author:MotokuraToruT,
pubmed-author:NakagawaMasahiroM,
pubmed-author:OgawaSeishiS,
pubmed-author:OshimaKumiK,
pubmed-author:Sakata-YanagimotoMamikoM,
pubmed-author:TsujinoShihoS
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
27
|
|
pubmed:volume |
79
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1351-7
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:15912103-Adult,
pubmed-meshheading:15912103-Aged,
pubmed-meshheading:15912103-Antibodies, Monoclonal,
pubmed-meshheading:15912103-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:15912103-Antibodies, Neoplasm,
pubmed-meshheading:15912103-Antigens, CD3,
pubmed-meshheading:15912103-CD4-Positive T-Lymphocytes,
pubmed-meshheading:15912103-CD8-Positive T-Lymphocytes,
pubmed-meshheading:15912103-Female,
pubmed-meshheading:15912103-Graft vs Host Disease,
pubmed-meshheading:15912103-Haplotypes,
pubmed-meshheading:15912103-Histocompatibility Testing,
pubmed-meshheading:15912103-Humans,
pubmed-meshheading:15912103-Incidence,
pubmed-meshheading:15912103-Lymphocyte Count,
pubmed-meshheading:15912103-Male,
pubmed-meshheading:15912103-Middle Aged,
pubmed-meshheading:15912103-Peripheral Blood Stem Cell Transplantation,
pubmed-meshheading:15912103-Survival Analysis,
pubmed-meshheading:15912103-Transplantation Chimera
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
In vivo alemtuzumab enables haploidentical human leukocyte antigen-mismatched hematopoietic stem-cell transplantation without ex vivo graft manipulation.
|
|
pubmed:affiliation |
Department of Cell Therapy and Transplantation Medicine, University of Tokyo Hospital, Hongo, Tokyo, Japan. ycanda-tky@umin.ac.jp
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
